Basel, March 22, 2018 – Novartis announced today that the US Food and Drug Administration (FDA) expanded the indication for Tasigna (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or older with…Original Article
Novartis Drug Tasigna Approved by FDA to Treat Children with Rare Form of Leukemia
